Last updated on October 2018

A Study of Brexpiprazole in Patients With Major Depressive Disorder

Brief description of study

The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of brexipiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy (ADT) in patients with Major Depressive Disorder.

Clinical Study Identifier: NCT03697603

Contact Investigators or Research Sites near you

Start Over

Nanko-kokorono clinic

Fukushima, Japan
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.